SHANGHAI, CHINA, May 9, 2026 – JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced the presentation of preclinical data for its two autologous anti-CD19/CD20 dual CAR-T products, JWCAR201 and JWCAR239, at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT 2026). Both JWCAR201 and JWCAR239 have entered clinical trials with initial positive results. Both products have now entered clinical trials and shown initial positive signals. The data presented here further reveal their potential mechanisms and therapeutic value in overcoming antigen escape, improving cell persistence, and enhancing antitumor activity.
JWCAR201:
Abstract Title: JWCAR201: An anti-CD19/CD20 dual CAR-T cell therapy manufactured using a rapid and automated platform exhibits enhanced antitumor efficacy and prevents antigen escape
Abstract ID: 1179
Presentation Type: Poster
Presentation Day: 05/12/2026
Relapse due to antigen escape, including ligand down regulation or loss of expression, remains a major cause of poor post-treatment in patients treated with anti-CD19 CAR-T cells. JWCAR201 is a JW self-developed autologous chimeric antigen receptor (CAR) T cell therapy targeting both CD19 and CD20. JWCAR201 is manufactured using a rapid and automated process, aiming to deliver a more potent, timely, and cost-effective CAR-T therapy.
Results
- Compared with anti-CD19 CAR-T cells, JWCAR201 displayed significantly enhanced cytotoxicity against diverse antigen-positive target cells in vitro. Moreover, JWCAR201 demonstrated superior antitumor efficacy than anti-CD19 CAR-T cells in various xenograft mouse models in vivo, while no significant toxicities was observed.
- Compared with traditionally manufactured CAR-T cells, rapidly manufactured JWCAR201 CAR-T cells displayed more sustained tumor killing and greater T cell expansion in an in vitro repeated antigen stimulation model, with demonstrated superior antitumor efficacy in vivo.
Conclusions: JWCAR201 demonstrated enhanced cytotoxicity against diverse antigen-positive target cells in vitro and effectively overcame relapse driven by tumor antigen loss in vivo. JWCAR201 generated using a rapid and automated manufacturing platform exhibited superior antitumor activity and enhanced expansion. These findings indicated JWCAR201, benefiting from a rapid and automated manufacturing platform, can address antigen escape as a clinically promising dual-targeting CAR-T therapy.
JWCAR239：
Abstract Title: JWCAR239: An enhanced anti-CD19/CD20 dual CAR-T therapy enabled by armored modules for persistence, co-stimulation and immune shielding
Abstract ID: 3249
Presentation Type: Poster
Presentation Day: 05/14/2026
In addition to antigen escape, several factors limit CAR-T therapy responses, including reduced T-cell survival due to activation-induced cell death (AICD), diminished co-stimulation resulting from CD58 aberrations in target cells, and functional suppression within the immunosuppressive tumor microenvironment (TME). To address these challenges, we developed JWCAR239, an enhanced anti-CD19/CD20 dual CAR-T cell therapy incorporating armored modules designed to promote persistence, augment co-stimulation and provide immune shielding.
Results
- In vitro, JWCAR239 1) displayed improved persistence and cytotoxicity under FasL-induced apoptotic stress, 2) exhibited stronger tumor-specific lysis and enhanced proliferation in the setting of CD58 loss, 3) preserved potent antitumor activity and robust proliferation in an immunosuppressive condition induced by TGFβ1, and 4) demonstrated higher potency and enhanced CAR-T cell expansion against tumor cells with varying antigen expression.
- In vivo, JWCAR239 demonstrated a favorable profile in xenograft model at a high CAR-T dose (2e6) with no overt toxicities. Notably, JWCAR239 demonstrated significantly superior in vivo persistence relative to the dual CAR-T control. On the other hand, JWCAR239 demonstrated superior tumor clearance in xenograft model at a very low CAR-T dose (5e4). Moreover, JWCAR239 displayed more rapid tumor clearance in CD58KO xenograft model.
Conclusions: These results demonstrate that the armored modules incorporated into JWCAR239 enhance CAR-T cell resistance to multiple immunosuppressive mechanisms in vitro. JWCAR239 further exhibits superior antitumor efficacy, increased persistence, and a favorable safety profile in vivo. Together, these preclinical findings highlight the potential of JWCAR239 to improve clinical outcomes with the incorporation of armored modules.
Innovating cures, shaping what's next — JW Therapeutics continues to deepen its innovation footprint in the cell therapy space, leveraging differentiated product designs and advanced technology platforms to steadily expand the potential applications of CAR-T therapies. Through iterative optimization and validation of data from pipeline candidates such as JWCAR201 and JWCAR239, gradually building a differentiated competitive landscape for its next-generation CAR-T product pipeline. With a focused effort to lead the global cell therapy innovation race, the company strives to bring hope of a cure to more patients.
About JW Therapeutics
JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China’s cell immunotherapy industry. For more information, please visit www.jwtherapeutics.com.
Forward-Looking Statements
The forward-looking statements are based on the management's expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website: www.jwtherapeutics.com/en/forward-looking-statements/.